Bruker Spatial Genomics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Bruker Spatial Genomics, a Bruker subsidiary founded in 2022 and based in San Diego, is pioneering a new frontier in spatial genomics with its PaintScape platform and jebFISH technology. This platform uniquely enables high-plex, direct imaging of the 3D genome within intact cell nuclei, providing unprecedented insights into chromatin architecture and genome organization at single-cell resolution. The technology, originally developed at Harvard University, addresses a critical gap in understanding how spatial genome dynamics influence gene regulation, cell state, and disease progression. As part of Bruker's strategic push into spatial biology, the company is positioned to empower basic research and translational studies in genetics and oncology.

Oncology

Technology Platform

The PaintScape™ platform, powered by proprietary jebFISH™ (joint extension barcoding FISH) technology, enables high-plex, direct in situ imaging and visualization of 3D genome architecture and chromatin organization in single cells at single-chromosome resolution.

Funding History

1

UndisclosedUndisclosedBruker CorporationJun 15, 2023

Opportunities

The company operates in the high-growth spatial biology market, addressing a significant gap in tools for direct, single-cell visualization of 3D genome organization.

Backing by Bruker provides immediate commercial scale, access to a global customer base, and resources to expand applications from basic research into translational and potentially clinical areas like cancer diagnostics.

Risk Factors

Key risks include technological adoption barriers due to platform complexity, competition from established genomic sequencing methods and other spatial omics players, and the challenge of proving the necessity of direct imaging data over inferential techniques.

Execution risk in integrating the technology into Bruker's portfolio and achieving commercial targets also exists.

Competitive Landscape

Bruker Spatial Genomics competes in the spatial genomics niche against sequencing-based 3D genome mapping techniques (e.g., Hi-C). Its direct imaging approach is differentiated but faces competition from other FISH-based multiplexing technologies. As part of Bruker, it also competes within the broader, crowded spatial biology instrument market against companies like 10x Genomics, NanoString, and Akoya Biosciences.

More companies in Diagnostics & Precision Medicine →More companies in United States →